Ceribell Inc (CBLL) Stock Forecast & Price Target

CeriBell is viewed favorably because its core point-of-care EEG platform is already showing durable traction, with active accounts rising to 712 hospitals, FY26 revenue guided to $114M-$117M, and gross margin at 92.3% despite adjusted EBITDA hovering around ($10M) as it prioritizes growth. Its outlook is strengthened by a broader addressable market now above $3.5B, as pediatric/neonate approvals, the Ceribell Delirium Monitor, and a late-stage stroke program add multiple new growth vectors beyond the core seizure market, where penetration remains below 4%. Further upside comes from recurring software and hardware upgrades, a growing sales force that should become more productive over time, and a strong clinical and reimbursement moat that supports continued account additions and utilization gains.

CeriBell is facing a negative fundamental setup because its subpar financial results suggest the Ceribell System is not yet translating innovation into durable operating strength, while competition from conventional EEG systems and new point-of-care alternatives could pressure adoption and pricing. The outlook is further weakened by unfavorable changes in insurance coverage and reimbursement, which can slow hospital uptake and compress realized revenue even if clinical demand exists. In addition, delays in new product launches and disappointing clinical results in expanded indications such as delirium and stroke, combined with tariff risk from China that could reduce gross margins and force more sourcing from Vietnam, create multiple headwinds to growth and profitability.